One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

Overall, strong Q1 revenues and improved margins led to net income of $856,962 without any Kinlytic-related revenues versus Q1 2024 net income of $2,455,379 inclusive of Kinlytic-related revenues.

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Microbix Biosystems Inc. ( OTCQX:MBXBF) Q1 2025 Earnings Conference Call February 13, 2025 11:00 AM ET Deborah Honig - Investor Relations Cameron Groome - Chief Executive Officer Jim Currie - Chief ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first ...

Inc. (Market cap: $34.46M) has reported its financial performance for the fourth quarter of 2023, highlighting a steady cash flow and strategic advancements in its clinical pipeline. According to ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...